TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10885861

Group type: EXPERIMENTAL
Intervention: Non-pharmacological interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Programmes training and supporting self-care skills, mobility, continence, orientation and participation in activities
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Research evidence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methods of measuring well-being
Number of subjects: 0
Study: 7750308

Group type: EXPERIMENTAL
Intervention: Music (M)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Silence (SIL)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Grey Noise (GN)
Number of subjects: 36
Study: 2405141

Group type: EXPERIMENTAL
Intervention: Human surfactant derived from amniotic fluid, administered within 12 hours of birth, with a second dose if needed.
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Human surfactant treatment
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Retreatment with surfactant
Number of subjects: 59
Study: 7138738

Group type: EXPERIMENTAL
Intervention: Paracetamol + codeine phosphate (400 mg + 30 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Plain paracetamol (400 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Paracetamol (400 mg)
Number of subjects: 24
Study: 30696408

Group type: EXPERIMENTAL
Intervention: SmartMoms® intervention (n = 37)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Usual Care (n = 17)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: SmartMoms® intervention and Usual Care
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Higher gestational weight gain
Number of subjects: 54
Study: 29303905

Group type: EXPERIMENTAL
Intervention: Pressure-controlled inverse ratio ventilation (PC-IRV)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Volume control ventilation (VCV)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Pressure control ventilation (PCV)
Number of subjects: 20
Study: 27535171

Group type: EXPERIMENTAL
Intervention: Music therapy (n = 29)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Standard care (n = 29)
Number of subjects: 58
Study: 25164908

Group type: EXPERIMENTAL
Intervention: Experimental arm (customized therapy based on BRCA1/RAP80 expression)
Number of subjects: 403

Group type: COMPARATOR
Intervention: Control arm (docetaxel/cisplatin)
Number of subjects: 403
Study: 22662606

Group type: EXPERIMENTAL
Intervention: Laparoscopic paraumbilical hernioplasty (GL)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional (open) umbilical hernioplasty (GO)
Number of subjects: 40
Study: 18712389

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Quality assessment of randomized controlled trials (RCTs)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Quality of report and design
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Statistical significance in quality differentiation
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Level of recommendation for adjuvant chemotherapy
Number of subjects: 26
Study: 17599778

Group type: EXPERIMENTAL
Intervention: Endonasal laser dacryocystorhinostomy
Number of subjects: 126

Group type: COMPARATOR
Intervention: Endonasal surgical dacryocystorhinostomy
Number of subjects: 126
Study: 15167520

Group type: EXPERIMENTAL
Intervention: Tc‐dextran joint scintigraphy
Number of subjects: 27
Study: 11600473

Group type: EXPERIMENTAL
Intervention: Endoscopic Papillary Balloon Dilation (EPBD)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Endoscopic Sphincterotomy (EST)
Number of subjects: 235
Study: 9702294

Group type: COMPARATOR
Intervention: Normal conditions (baseline)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adenomas or adenocarcinomas
Number of subjects: 0
Study: 8051620

Group type: EXPERIMENTAL
Intervention: Passive immunotherapy with HIV-1 neutralizing monoclonal antibodies
Number of subjects: 11
Study: 2497984

Group type: EXPERIMENTAL
Intervention: Cafergot P-B
Number of subjects: 254

Group type: COMPARATOR
Intervention: Cafergot
Number of subjects: 254
Study: 31152560

Group type: EXPERIMENTAL
Intervention: Simulation-based ultrasound training focusing on fetal weight scans
Number of subjects: 70

Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 70
Study: 30741965

Group type: EXPERIMENTAL
Intervention: Twirled noise over a unitary 2t-design for quantum circuits
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Local random circuits for twirling separable noisy channel over the Clifford group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stochastic noise estimation via average fidelity
Number of subjects: 0
Study: 28141662

Group type: EXPERIMENTAL
Intervention: 8-week dance-based aquatic exercise program
Number of subjects: 34
Study: 25183667

Group type: COMPARATOR
Intervention: Immersible ergocycle (Hydrorider®)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dryland ergocycle (Ergoline 800S)
Number of subjects: 20
Study: 24278914

Group type: EXPERIMENTAL
Intervention: One-piece implants
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Two-part implants
Number of subjects: 20
Study: 21679106

Group type: EXPERIMENTAL
Intervention: Standard platelet transfusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Slow platelet transfusion
Number of subjects: 0
Study: 19839993

Group type: EXPERIMENTAL
Intervention: Asenapine (10 mg BID on day 1; 5 or 10 mg BID thereafter; mean daily dosage 18.2 mg)
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Olanzapine (15 mg BID on day 1; 5-20 mg QD thereafter; mean daily dosage 15.8 mg)
Number of subjects: 488

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 488
Study: 16981102

Group type: EXPERIMENTAL
Intervention: AFE-guided biopsy plus four-quadrant biopsies
Number of subjects: 187

Group type: COMPARATOR
Intervention: Conventional endoscopic surveillance with four-quadrant biopsies
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: AFE in study phase 2
Number of subjects: 187

Group type: COMPARATOR
Intervention: Conventional endoscopy in study phase 2
Number of subjects: 187
Study: 14719427

Group type: EXPERIMENTAL
Intervention: VAMP Plus system (blood conservation device)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard arterial pressure line set (control group)
Number of subjects: 160
Study: 10913502

Group type: EXPERIMENTAL
Intervention: Lithium (administered for 4 weeks)
Number of subjects: 21
Study: 9299654

Group type: EXPERIMENTAL
Intervention: Cetirizine (5 mg)
Number of subjects: 687

Group type: EXPERIMENTAL
Intervention: Pseudoephedrine retard (120 mg)
Number of subjects: 687

Group type: EXPERIMENTAL
Intervention: Combination of cetirizine (5 mg) and pseudoephedrine retard (120 mg)
Number of subjects: 687

Group type: EXPERIMENTAL
Intervention: Combination of cetirizine and pseudoephedrine
Number of subjects: 687
Study: 8143888

Group type: EXPERIMENTAL
Intervention: Norfloxacin, Ofloxacin, Enoxacin, Ciprofloxacin, Lomefloxacin (200 mg three times daily for 3 consecutive days)
Number of subjects: 180
Study: 2872516

Group type: EXPERIMENTAL
Intervention: Total lymphoid irradiation (TLI; 1980 cGy)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham irradiation
Number of subjects: 40
Study: 28966335

Group type: EXPERIMENTAL
Intervention: Everolimus-Eluting Stents (EES)
Number of subjects: 1443

Group type: COMPARATOR
Intervention: Sirolimus-Eluting Stents (SES)
Number of subjects: 1443
Study: 26926020

Group type: EXPERIMENTAL
Intervention: Rapid maxillary expansion (RME)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (no orthodontic treatment)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Comparison between RME and control groups
Number of subjects: 33
Study: 24742255

Group type: EXPERIMENTAL
Intervention: Massage therapy (30 minutes twice weekly for 6 weeks)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Nonmassage touch/holding sham treatment (30 minutes twice weekly for 6 weeks)
Number of subjects: 36
Study: 22453648

Group type: EXPERIMENTAL
Intervention: Subtherapeutic CPAP for 2 weeks
Number of subjects: 41

Group type: COMPARATOR
Intervention: Therapeutic CPAP for 2 weeks
Number of subjects: 41
Study: 20085542

Group type: EXPERIMENTAL
Intervention: Ultrasound (US) guidance
Number of subjects: 110

Group type: COMPARATOR
Intervention: Neurostimulation (NS) and ultrasound (NSUS) guidance
Number of subjects: 110
Study: 18727530

Group type: EXPERIMENTAL
Intervention: Tetracycline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Internal Standard (Oxytetracycline)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Liquid chromatographic/tandem mass spectrometric method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Method validation parameters
Number of subjects: 0
Study: 15972906

Group type: EXPERIMENTAL
Intervention: Valgus corrective brace
Number of subjects: 12

Group type: COMPARATOR
Intervention: Simple hinged brace
Number of subjects: 12
Study: 12204348

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10470326

Group type: EXPERIMENTAL
Intervention: Antagonists to inflammatory cytokines IL-1 and TNF
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 8916311

Group type: EXPERIMENTAL
Intervention: Idarubicin (IDA) plus cytarabine (Ara-C)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Daunorubicin (DNR) plus cytarabine (Ara-C)
Number of subjects: 32
Study: 1919952

Group type: EXPERIMENTAL
Intervention: Cow's milk
Number of subjects: 73

Group type: COMPARATOR
Intervention: Chicken-based formula
Number of subjects: 73
Study: 6805713

Group type: EXPERIMENTAL
Intervention: After-exercise thermography
Number of subjects: 112

Group type: COMPARATOR
Intervention: Fibrinogen-uptake test
Number of subjects: 112
Study: 31618539

Group type: EXPERIMENTAL
Intervention: Surgical treatment (laparoscopic Nissen fundoplication)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Active medical treatment (omeprazole plus baclofen, with desipramine added depending on symptoms)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control medical treatment (omeprazole plus placebo)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Active medical treatment
Number of subjects: 78
Study: 27818283

Group type: EXPERIMENTAL
Intervention: Tailored video intervention with newsletters (5 during and 3 after pregnancy) and videos (3 during and 2 after pregnancy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care approaches (newsletters and videos on healthy pregnancy topics)
Number of subjects: 0
Study: 24820653

Group type: EXPERIMENTAL
Intervention: Oral alendronate (ALN)
Number of subjects: 299

Group type: COMPARATOR
Intervention: Not receiving oral alendronate (Control)
Number of subjects: 299
Study: 23746015

Group type: EXPERIMENTAL
Intervention: Emergent surgical reduction and fixation
Number of subjects: 36

Group type: COMPARATOR
Intervention: Secondary operative fixation after emergent closed reduction
Number of subjects: 36
Study: 21930149

Group type: EXPERIMENTAL
Intervention: GSM mobile phone RF exposure for 15 minutes
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sham exposure for 15 minutes
Number of subjects: 26
Study: 18947980

Group type: EXPERIMENTAL
Intervention: Capsule of olive leaf extract
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Liquid extract of olive leaf
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 45
Study: 17909140

Group type: EXPERIMENTAL
Intervention: Block play intervention (distribution of 2 sets of building blocks)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Control group (no block play)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Block play intervention
Number of subjects: 175

Group type: COMPARATOR
Intervention: Hyperactivity scores
Number of subjects: 175
Study: 15177817

Group type: EXPERIMENTAL
Intervention: Lexical decision task performance in aphasic patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lexical decision task performance in normal readers
Number of subjects: 0
Study: 12452733

Group type: EXPERIMENTAL
Intervention: Ionic low-osmolar contrast media (LOCM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-ionic iso-osmolar contrast media (IOCM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ionic high-osmolar contrast media (HOCM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-ionic low-osmolar contrast media (LOCM)
Number of subjects: 0
Study: 9806313

Group type: EXPERIMENTAL
Intervention: Low energy density (LED) diet (373 kJ/100 g)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Medium energy density (MED) diet (549 kJ/100 g)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: High energy density (HED) diet (737 kJ/100 g)
Number of subjects: 6
Study: 8536121

Group type: EXPERIMENTAL
Intervention: IV fenoldopam (FNP)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Sodium nitroprusside (NTP)
Number of subjects: 183
Study: 2375667

Group type: EXPERIMENTAL
Intervention: Progressive resistance exercise (PRE) three times per week for six weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no exercise beyond usual daily activities)
Number of subjects: 24
Study: 333856

Group type: EXPERIMENTAL
Intervention: Bromocriptine (2.5-40 mg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 31772085

Group type: EXPERIMENTAL
Intervention: SIDCER ICF
Number of subjects: 210

Group type: COMPARATOR
Intervention: Conventional ICF
Number of subjects: 210
Study: 29200424

Group type: EXPERIMENTAL
Intervention: MeCFES assisted TOT (M‐TOT)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Conventional rehabilitation care including TOT (C‐TOT)
Number of subjects: 82
Study: 25785522

Group type: EXPERIMENTAL
Intervention: Modified cardiovascular component of the Sequential Organ Failure Assessment score
Number of subjects: 16386

Group type: COMPARATOR
Intervention: Cardiovascular component of the Sequential Organ Failure Assessment score
Number of subjects: 16386

Group type: EXPERIMENTAL
Intervention: Modified Sequential Organ Failure Assessment score
Number of subjects: 16386

Group type: COMPARATOR
Intervention: Existing Sequential Organ Failure Assessment score
Number of subjects: 16386
Study: 23643372

Group type: EXPERIMENTAL
Intervention: Yoga program offered in place of a semester of physical education classes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (physical education classes)
Number of subjects: 0
Study: 20668835

Group type: EXPERIMENTAL
Intervention: Non-anatomical double-bundle hamstring tendons autograft
Number of subjects: 79

Group type: COMPARATOR
Intervention: Single-bundle bone-patellar tendon-bone autograft
Number of subjects: 79
Study: 19221692

Group type: EXPERIMENTAL
Intervention: Huperzine A (HupA), oral administration for 8-24 weeks at a dosage of 300-500 microg daily
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 17199237

Group type: EXPERIMENTAL
Intervention: Dissatisfied with performance of valued activities (n = 71)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Satisfied with performance of valued activities (n = 135)
Number of subjects: 206
Study: 15347372

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (FPANS) 400 microg b.i.d.
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (FPANS) 800 microg b.i.d.
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo b.i.d.
Number of subjects: 162
Study: 11686218

Group type: EXPERIMENTAL
Intervention: Allopurinol 100 mg twice daily
Number of subjects: 184

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study: 11284463

Group type: EXPERIMENTAL
Intervention: rizatriptan 10 mg
Number of subjects: 1268

Group type: COMPARATOR
Intervention: sumatriptan 100 mg
Number of subjects: 1268
Study: 8163058

Group type: EXPERIMENTAL
Intervention: Maximal microvascular hyperaemic response to local heating in subjects with fasting hyperglycaemia (1.01 [0.71-1.57]V, median and range)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Maximal microvascular hyperaemic response to local heating in control subjects (1.41 [1.32-2.13]V, p < 0.001)
Number of subjects: 22
Study: 2971564

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (IB)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Salbutamol (S)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Salbutamol (S) after pretreatment with Ipratropium bromide (IB)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Salbutamol (S) after pretreatment with Salbutamol (S)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Combination treatment of Salbutamol (S) and Ipratropium bromide (IB)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Maximal effect of Salbutamol (S)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Maximal effect of Ipratropium bromide (IB)
Number of subjects: 15
Study: 31611155

Group type: EXPERIMENTAL
Intervention: Kinesio Taping (KT) applied to respiratory muscles, 2 days a week for 6 weeks
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (Deep breathing exercises)
Number of subjects: 27
Study: 30773576

Group type: EXPERIMENTAL
Intervention: Persistent high-frequency noise from dental equipment
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Working hours per week
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Gender (males vs females)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Years of experience
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Median count of severely affected hearing frequencies
Number of subjects: 90
Study: 29188882

Group type: EXPERIMENTAL
Intervention: Intensive diet-induced weight loss (D)
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Intensive diet-induced weight loss plus exercise (D+E)
Number of subjects: 388

Group type: COMPARATOR
Intervention: Exercise (E)
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Intensive diet-induced weight loss (D) and Intensive diet-induced weight loss plus exercise (D+E)
Number of subjects: 388
Study: 25795076

Group type: EXPERIMENTAL
Intervention: MPa200Z regimen (moxifloxacin, 200 mg pretomanid, and pyrazinamide)
Number of subjects: 207

Group type: COMPARATOR
Intervention: HRZE regimen (isoniazid, rifampicin, PZA, and ethambutol)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: DRMPa200Z regimen (moxifloxacin, 200 mg pretomanid, and pyrazinamide for drug-resistant tuberculosis)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: MPa100Z regimen (moxifloxacin, 100 mg pretomanid, and pyrazinamide)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: MPa200Z regimen
Number of subjects: 207

Group type: COMPARATOR
Intervention: HRZE regimen
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: DRMPa200Z regimen
Number of subjects: 207
Study: 23698396

Group type: EXPERIMENTAL
Intervention: Lixisenatide 20 μg once daily
Number of subjects: 634

Group type: COMPARATOR
Intervention: Exenatide 10 μg twice daily
Number of subjects: 634
Study: 21593296

Group type: EXPERIMENTAL
Intervention: Liraglutide plus insulin in C‐peptide positive patients
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Liraglutide plus insulin in C‐peptide negative patients
Number of subjects: 29

Group type: COMPARATOR
Intervention: Insulin monotherapy in C‐peptide negative patients
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Liraglutide treatment
Number of subjects: 29
Study: 19619705

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 533

Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 533
Study: 16845354

Group type: EXPERIMENTAL
Intervention: Active involvement and intervention using early mobilization
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard intervention of rest and cervical collar immobilization
Number of subjects: 0
Study: 12957683

Group type: EXPERIMENTAL
Intervention: Calcium dobesilate
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 10953261

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 9816131

Group type: EXPERIMENTAL
Intervention: 13-cis retinoic acid (13cRA) treatment for 6 months
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Smoking cessation during treatment
Number of subjects: 69

Group type: COMPARATOR
Intervention: Normal bronchial biopsies
Number of subjects: 69
Study: 1727833

Group type: COMPARATOR
Intervention: 19NT‐HPP alone (400 mg loading dose, followed by 200 mg every 3 weeks for 24 weeks)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 19NT‐HPP with buserelin (3.3 or 6.6 mg implant after initial androgen suppression)
Number of subjects: 24
Study: 6421140

Group type: EXPERIMENTAL
Intervention: Flecainide, 200 mg twice daily
Number of subjects: 25

Group type: COMPARATOR
Intervention: Disopyramide, 150 mg 4 times daily
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 25

Group type: COMPARATOR
Intervention: Disopyramide
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Flecainide and Disopyramide
Number of subjects: 25
Study: 30689507

Group type: EXPERIMENTAL
Intervention: PCV15-A
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PCV15-B
Number of subjects: 0

Group type: COMPARATOR
Intervention: PCV13
Number of subjects: 0
Study: 28729180

Group type: EXPERIMENTAL
Intervention: Afatinib (40 mg/d)
Number of subjects: 795

Group type: COMPARATOR
Intervention: Erlotinib (150 mg/d)
Number of subjects: 795
Study: 26311707

Group type: EXPERIMENTAL
Intervention: Total mastic (TM, n=72) receiving daily a total dose of 1 g of crude CMG (330 mg capsules, tid)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Polymer-free mastic (PFM, n=33) receiving daily a total dose of 1 g of polymer free mastic (330 mg caps, tid)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Powder mastic (PM, n=28) receiving daily a total dose of 2 g of crude CMG
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control group (C, n=23) receiving placebo
Number of subjects: 156
Study: 24674455

Group type: EXPERIMENTAL
Intervention: Physical exercise (45-min moderate-intensity workout)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Food deprivation (24-hr period)
Number of subjects: 6
Study: 22849509

Group type: EXPERIMENTAL
Intervention: Father inclusive intervention
Number of subjects: 533

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 533
Study: 20189092

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (lead-in phase)
Number of subjects: 427